VR461

VR461 is an inhaled anti-fungal drug candidate developed by Vectura Group, a specialist in inhaled therapeutics. It was designed to treat fungal infections in patients with underlying chronic lung diseases, such as cystic fibrosis or severe asthma, where fungal colonization (e.g., *Aspergillus*) can lead to significant morbidity. The drug utilizes Vectura's proprietary inhalation technology to deliver the anti-fungal agent directly to the site of infection in the lungs, aiming to achieve high local concentrations while minimizing systemic exposure and associated toxicities. As of 2010, the program was in pre-clinical development with plans to enter Phase 1 clinical trials in 2011. However, the product has not appeared in more recent company pipelines, suggesting that development may have been discontinued or deprioritized following Vectura's strategic shifts and subsequent acquisition by Philip Morris International.

Other names

Vectura inhaled anti-fungal